Is Ketamine Tablet As Effective As IV?

This is one of the most commonly asked questions in ketamine therapy, and it deserves a complete, honest answer based on available evidence. The short answer: ketamine tablet is generally less effective than IV for acute antidepressant induction, but may be comparably effective for maintenance — and may be the more practical choice for many patients.

Why the Comparison Is Complicated

Before getting into the evidence, it's worth understanding why this question doesn't have a simple yes/no answer:

Different pharmacological experiences: IV and ketamine tablet are not just different doses of the same drug — they produce fundamentally different ratios of ketamine to norketamine due to first-pass metabolism. This means they are pharmacologically distinct experiences with potentially different therapeutic mechanisms, not simply weaker vs. stronger versions of the same thing.

Different uses: IV is typically used for acute induction; oral is often used for maintenance. Comparing them at the same stage of treatment for the same patient (which no study has done in a randomized way) is difficult.

No head-to-head randomized trial: No study has randomized patients to IV vs. ketamine tablet with the same outcome measures. All comparisons are indirect. For a thorough review of the evidence, see our article on oral vs. IV comparative research.

What the Bioavailability Challenge Means

The fundamental challenge for ketamine tablet effectiveness is its low bioavailability: only 10–25% of an oral dose reaches systemic circulation. This means:

• At equivalent mg/kg doses, oral produces far lower peak plasma levels of ketamine than IV
• The primary NMDA receptor blocker (ketamine) is present in much lower concentrations in the brain after oral dosing than after IV
• A much larger oral dose would be theoretically needed to achieve comparable plasma levels to IV

However, this doesn't mean oral is necessarily less effective therapeutically, because:

• Oral produces more norketamine, which has its own antidepressant properties
• Oral produces more (2R,6R)-hydroxynorketamine (HNK), a potentially important antidepressant metabolite
• The slower onset and longer duration of oral may produce sustained synaptic changes through a different kinetic profile
• The brain may not need the same plasma levels to produce comparable neuroplasticity over a longer time course

What the Evidence Shows

Acute Antidepressant Response

For acute response (first 24–72 hours of treatment):

IV ketamine evidence: Very robust. Multiple randomized controlled trials, meta-analyses, and systematic reviews consistently show response rates of 50–70% within 24 hours, with very consistent results across institutions and research groups.

Ketamine tablet evidence: Less robust. Several open-label studies show response rates of 50–77%, but controlled trials are fewer and smaller. The Swainson et al. pilot RCT (2020) showed ketamine tablet outperformed midazolam placebo, but was underpowered for definitive conclusions.

Assessment: IV likely produces more reliable acute response with stronger evidence. For patients needing rapid, reliable antidepressant induction — particularly for severe depression or suicidality — IV has the stronger evidence base.

Maintenance Response

For ongoing maintenance therapy (weeks to months):

IV maintenance evidence: Booster infusions (monthly or as-needed) maintain response in many patients, but require ongoing clinic visits and expense. No large controlled trial has specifically examined optimal IV maintenance schedules.

Oral maintenance evidence: Follow-up data from ketamine tablet programs suggests that ongoing ketamine tablet sustains response effectively in most initial responders. Some programs have successfully transitioned patients from IV induction to oral maintenance with maintained antidepressant effects.

Assessment: The evidence does not clearly favor IV over oral for maintenance. Oral's practical advantages (home-based, lower cost, more flexible scheduling) are significant.

Chronic Pain

For chronic pain management, ketamine tablet is arguably the more effective choice for long-term use because:

• Continuous daily dosing provides sustained NMDA receptor modulation
• IV infusions for pain are typically done as periodic "boosters" rather than continuously
• The oral route is practical for daily analgesic dosing; IV is not

The "Not Equal But Not Inferior" Framework

A useful way to think about this: Oral and IV ketamine may not be equivalent, but they may be not clinically inferior for the purposes patients most commonly use them for.

For acute severe TRD induction: IV is likely superior.
For maintenance after achieving remission: Oral may be non-inferior.
For chronic pain: Oral may be superior (daily dosing practicality).
For patients who cannot access IV clinics: Oral is clearly the better option because it is accessible.

A treatment that is theoretically somewhat less potent but that a patient can actually access, afford, and maintain is, in practice, more effective than a theoretically superior treatment they can't use.

Real-World Effectiveness vs. Efficacy

Clinical trials measure "efficacy" — performance under ideal trial conditions. Real-world "effectiveness" accounts for:

• Whether patients can access and afford the treatment
• Whether patients adhere to the treatment schedule
• Whether the treatment fits into patients' lives

IV ketamine requires clinic visits twice weekly during induction, monthly boosters, transportation, and $400–$800 per session. For many patients with depression — who often struggle with motivation, energy, and logistical challenges — this is a significant barrier.

Ketamine tablet, taken at home, may have lower trial efficacy but higher real-world effectiveness for the large population of patients who cannot access IV clinics.

Making the Decision

Questions to guide the IV vs. oral decision:

1. How severe is my depression? Very severe or acutely suicidal → IV is preferable for induction. Moderate TRD with some functioning → oral may be adequate starting point.
2. Can I access an IV ketamine clinic? If not, ketamine tablet is the realistic option.
3. What can I afford? IV at $400–$800/session vs. oral at $200–$500/month is a meaningful financial difference.
4. What is my treatment goal? Acute response in weeks → IV advantage. Long-term maintenance → oral practical advantage.
5. Have I tried IV already? If IV worked, transitioning to oral for maintenance is a reasonable strategy.

The Bottom Line

Ketamine tablet is not as effective as IV for acute antidepressant induction based on available evidence. But "not as effective" is not "ineffective" — it produces meaningful antidepressant responses in 50–70% of appropriately selected patients, operates through a distinct and potentially complementary pharmacological profile, and provides significant practical advantages for maintenance therapy. For many patients, ketamine tablet is the right choice — not a compromise, but the genuinely optimal approach for their situation.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches